Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Takeda Licenses Orexigen Obesity Drug

by Ann M. Thayer
September 13, 2010 | A version of this story appeared in Volume 88, Issue 37

Japan’s Takeda Pharmaceutical is paying $50 million to license an obesity therapy being developed by Orexigen Therapeutics. Takeda will have exclusive North American marketing rights for Contrave, a combination of the drugs naltrexone and bupropion that is believed to address both biological and behavioral aspects of obesity. Orexigen, which filed for FDA approval at the end of March, could also receive regulatory and other milestone payments totaling more than $1 billion.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.